Abstract:The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned from targeting bromodomain extraterminal domain (BET) proteins into targeting non-BET bromodomains. The two most relevant non-BET bromodomain oncology targets are cyclic AMP response element-binding protein (CBP) and E1A binding protein P300 (EP300). To explore the growing CBP/EP300 interest, we developed a highly efficient two-step synthetic route for dimethylisoxazole-attached imidazo[1,2-a]pyridine scaffold-containing inhibitors. Our efficient two-step reactions enabled high-throughput synthesis of compounds designed by molecular modeling, which together with structure–activity relationship (SAR) studies facilitated an overarching understanding of selective targeting of CBP/EP300 over non-BET bromodomains. This led to the identification of a new potent and selective CBP/EP300 bromodomain inhibitor, UMB298 (compound 23, CBP IC50 72 nM and bromodomain 4, BRD4 IC50 5193 nM). The SAR we established is in good agreement with literature-reported CBP inhibitors, such as CBP30, and demonstrates the advantage of utilizing our two-step approach for inhibitor development of other bromodomains.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02232?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02232</a>.Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_001.csv">CSV</a>)BromoSCAN, differential scanning fluorometry (DSF), and cellular activity data of compounds 7, 16, and 23; crystallographic data collection and refinement statistics of compound 23; 1H NMR and 13C NMR of representative compounds; and HPLC traces of compounds 7, 16, and 23 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_002.pdf">PDF</a>)Homology (docking) models of BRD4_5BT4_Cpd7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_003.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_004.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_005.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-3 (UMB274) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_006.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-4 (UMB278) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_007.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_008.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_009.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_010.pdb">PDB</a>)Cocrystallographic data of compound 23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_011.pdb">PDB</a>)This article has not yet been cited by other publications.

Development of methyl isoxazoleazepines as inhibitors of BET

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1 H-pyrrolo[2,3- c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain

Selective inhibition of BET bromodomains

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Development of Dimethylisoxazole-Attached Imidazo[1,2- a ]pyridines as Potent and Selective CBP/P300 Inhibitors

Naphthyridines as novel BET family bromodomain inhibitors

Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy

Discovery and characterization of small molecule inhibitors of the BET family bromodomains

Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain

Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections

Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.

Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors

3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands

Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787

BET bromodomain inhibitors: fragment-based in silico design using multi-target QSAR models

Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia

Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization